Info@ThinkPinkRocks.com

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show.

Taken from:
No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

Share

Leave a Reply